表紙
市場調查報告書
商品編碼
924449

全球動物診斷市場:成長,趨勢,及預測

Veterinary Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 132 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球動物診斷市場的相關調查,提供市場機會和趨勢,成長及阻礙因素,各技術·動物類型·地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 寵物及擁有人口的增加
    • 人獸通用感染疾病的負擔增加
    • 製藥公司的寵物保險及動物衛生投資的增加
  • 市場阻礙因素
    • 寵物照護費用的增加
    • 低中所得國標準以下的醫療設施
  • 波特的五力分析

第5章 市場區隔

  • 各技術
    • 免疫診斷
    • 臨床生物化學
    • 分子診斷
    • 血液學
    • 尿液檢查
    • 其他
  • 各動物類型
    • 寵物
    • 家畜動物
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Abaxis, Inc
    • Biomerieux SA
    • Heska Corporation
    • Idexx Laboratories
    • IDVet
    • Qiagen NV
    • Randox Laboratories, Ltd
    • Thermo Fisher Scientific
    • Virbac
    • Zoetis, Inc

第7章 市場機會及今後趨勢

目錄
Product Code: 56273

The veterinary diagnostics market registered a market size of USD 4,758.9 million in 2020, and it is expected to reach USD 12,635.2 million by 2026, with a CAGR of nearly 11.7% during the forecast period, 2021-2026. The factors driving the market growth include increased animal healthcare expenditure, rising incidence of zoonotic diseases, and the growing number of veterinary practitioners as well as disposable income in the developing regions.

Globally, the COVID-19 pandemic has highlighted the adaptability and response by veterinary diagnosticians to an emerging infectious disease and their role in maintaining animal health and protecting human public health. In addition, as per the University of Glasgow, during the COVID-19 pandemic, COVID-19 has been reported in domestic cats, dogs, and non-domestic cats.

Several zoo animals have also been reported to have been infected by the virus. For instance, in May 2020, the United States Department of Agriculture's (USDA) National Veterinary Services Laboratories confirmed SARS-CoV-2 in one tiger at a zoo in New York. This is the first instance of a tiger being infected with COVID-19. Samples from this tiger were taken and tested after several lions and tigers at the zoo showed symptoms of respiratory illness.

The diagnostic tests are generally performed by taking feces, tissue samples, and the blood of animals. Worldwide, increasing pet ownerships and migration of people from towns to urban localities across developed and emerging markets are increasing the demand for veterinary diagnostics.

Also, the rise in hemorrhagic viral disease and zoonotic and foodborne diseases has increased the responsibility of owners and animal healthcare organizations to invest more in their healthcare. For instance, according to the Center for Infectious Disease Research and Policy (CIDRAP) 2020 report, based on nasal swabbing, Chinese scientists isolated 179 swine influenza viruses from pigs across 10 Chinese provinces between 2011 and 2018.

Furthermore, in 2018, according to the data published by the American Pet Products Association (APPA), the total pet healthcare expenditure was USD 72.13 billion, as compared to USD 69.51 billion in 2017. Therefore, the rise in disposable income is another major factor influencing animal health expenditure. Apart from the per capita animal health expenditure, industries across the world are also spending more on veterinary disease diagnosis and treatment.

According to the Animal Health Institute (AHI), every year, the AHI member companies spend 10%-12% of their sales to invest in new innovations in veterinary health. Hence, numerous medical devices have been developed by scientists, as a result of which the diagnosis has improved radically, along with prevention and treatment of animal health issues.

In case of developed markets, many private insurance companies are attracting owners and companies, which is boosting the growth of the market. However, the high cost of pet care and imaging devices and the lack of veterinarians are impeding the veterinary diagnostics market growth.

Key Market Trends

The Molecular Diagnostics Segment is Estimated to Hold a Significant Market Share Over the Forecast Period

In 2019, the molecular diagnostic segment generated a revenue of around USD 514.73 million. Globally, the use of molecular diagnostics has been increasing for the detection of veterinary pathogens. It involves the detection of pathogens directly by checking the presence of RNA or DNA in the host or indirectly by prior amplification of the genome of the infectious agent. Moreover, modifications in a molecular diagnostic test like PCR have generated a vast array of fast, reliable, and specific assays that have widespread applications in veterinary diagnostics.

During the COVID-19 pandemic, worldwide, animal health authorities carried out tests to understand how the virus is affecting animals. The research studies and testing show that felines are more susceptible than other animals. The most recent development in the veterinary diagnostics market is the introduction of a PCR panel for testing the COVID-19 virus in animals by IDEXX Laboratories Inc. in April 2020, which has tested up to 6,000 specimens.

Globally, people are showing interest or importance toward rapid tests that help in providing results within 24 hours or during the initial examination period of an animal. Thus, molecular diagnostics are important diagnostic tools for both farm animals and pets to protect them from diseases.

As per the World Organization for Animal Health, as of 2020, there are approximately 117 animal diseases, infections, and infestations. In addition, with the rising pet ownership and increasing awareness, the veterinary diagnostics market is expected to grow over the forecast period.

North America is Expected to Hold a Major Market Share Over the Forecast Period

In the North American region, in countries such as the United States and Canada, there are an increasing number of people adopting pets, and several facilities provide pet care services. For instance, according to the 2019-2020 National Pet Owners Survey conducted by the American Pet Products Association (APPA), 67% of households or about 85 million families in the United States own a pet.

In April 2020, the CDC and the US Department of Agriculture's (USDA) National Veterinary Services Laboratories (NVSL) confirmed the cases of two pet cats that were infected by COVID-19. These were the first pets in the United States to test positive for the disease.

As per the American Veterinary Medical Association, in April 2020, the United States announced the availability of a reverse transcriptase-polymerase chain reaction (RT-PCR) test for SARS-CoV-2 in domestic animals, including cats and dogs.

Furthermore, increasing investments in pet animals to protect them and improve the human-animal relationship are driving the veterinary diagnostics market in this region. Also, the steady importance given to agricultural contribution in these countries makes the owner more responsible for better care for farm animals, which is expected to drive the market growth over the forecast period.

Competitive Landscape

The veterinary diagnostics market is moderately consolidated competitive. The major market players are focusing on improved diagnostics techniques for animal care, especially protecting the animals from diseases due to changing weather conditions. For instance, in January 2018, IDEXX launched its IDEXX Catalyst SDMA Test to analyze kidney function in companion animals. Some of the major players in the market are bioMerieux SA, Idexx Laboratories, Virbac, Thermo Fisher Scientific, and Zoetis Inc., among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Pet Ownership and Animal Health Expenditure
    • 4.2.2 Increased Burden of Animal Zonotic Diseases
    • 4.2.3 Growing Pet Insurance and Animal Health Investments by Pharmaceutical Companies
  • 4.3 Market Restraints
    • 4.3.1 Lack of Veterinarians
    • 4.3.2 High Cost of Pet Care and Imaging Devices
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product
    • 5.1.1 Instruments
    • 5.1.2 Kits and Reagents
    • 5.1.3 Software and Services
  • 5.2 By Technology
    • 5.2.1 Immunodiagnostics
    • 5.2.2 Clinical Biochemistry
    • 5.2.3 Molecular Diagnostics
    • 5.2.4 Hematology
    • 5.2.5 Other Technologies
  • 5.3 By Animal Type
    • 5.3.1 Companion Animals
      • 5.3.1.1 Dogs
      • 5.3.1.2 Cats
      • 5.3.1.3 Other Companion Animals
    • 5.3.2 Livestock Animals
      • 5.3.2.1 Cattle
      • 5.3.2.2 Swine
      • 5.3.2.3 Poultry
      • 5.3.2.4 Other Livestock Animals
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 bioMerieux SA
    • 6.1.2 Heska Corporation
    • 6.1.3 Idexx Laboratories
    • 6.1.4 IDVet
    • 6.1.5 Randox Laboratories Ltd
    • 6.1.6 Thermo Fisher Scientific
    • 6.1.7 Virbac
    • 6.1.8 Zoetis Inc.
    • 6.1.9 BIOCHEK BV
    • 6.1.10 INDICAL Bioscience GmbH​

7 MARKET OPPORTUNITIES AND FUTURE TRENDS